Muthu Vaduganathan (@mvaduganathan) / X

Muthu Vaduganathan

7,341 posts

Muthu Vaduganathan

@mvaduganathan

Cardiologist & Trialist @BrighamWomens @harvardmed | AE @JACCJournals | Podcast #DontMissABeat & #HFinFocus | Disclosures: bit.ly/3icLqlg

Cambridge, MA

connects.catalyst.harvard.edu/Profiles/displ…

Joined July 2017

Pinned
Muthu Vaduganathan
@mvaduganathan
Oct 6, 2025
🔥 New in @NatureMedicine How do you communicate lifetime benefits expected with HFpEF therapies? New data from 3 RCTs (#DELIVER #FINEARTS #PARAGON) estimate up to *5 years* of event-free survival w combination Rx #GDMT for HFpEF has finally arrived! 🔗nature.com/articles/s4159…
37K
Muthu Vaduganathan
@mvaduganathan
May 24, 2024
🚨#FLOW: The most anticipated trial of the year now published in @NEJM with #ERA24 Semaglutide 1.0mg once weekly disease modifying with kidney, CV, & mortality benefits in people w T2D+CKD, cementing itself as a new pillar of care. 🧵 on key thoughts 👇🏾 nejm.org/doi/full/10.10…
158K
Muthu Vaduganathan
@mvaduganathan
Jul 16, 2025
Just 5 years ago, HFpEF was described as the “stepchild” of HF with no approved therapies. Today, there are 5 US FDA therapies: ✅ Empagliflozin (#EMPEROR) ✅ Dapagliflozin (#DELIVER) ✅ Sotagliflozin (#SOLOISTWHF) ✅ Sacubitril/Valsartan (#PARAGONHF) ✅ Finerenone (#FINEARTSHF)
42K
Muthu Vaduganathan
@mvaduganathan
Mar 30, 2020
For decades, the elegant #RAAS has been pharmacologically targeted. SARS-CoV-2 hijacks this system in #COVID19 New @NEJM Special Report @orlyvardeny @tmmichelangelo #McMurray #Pfeffer @scottdsolomon Can #RAAS be regulated to protect against #COVID19? 📎 nejm.org/doi/full/10.10…
Muthu Vaduganathan
@mvaduganathan
May 1, 2021
Dapagliflozin becomes 1st #SGLT2i in class to be triple indicated (#T2D #HF #CKD) @US_FDA update likely represents the largest expansion to an at-risk population, now approved down to eGFR 25 for organ protection. Stay tuned: #TRANSLATEHF data on intersection of HF+CKD #ACC2021
Muthu Vaduganathan
@mvaduganathan
Sep 1, 2024
🔥 A new therapeutic era in #HFpEF #FINEARTSHF with definitive evidence supporting the role of the non-steroidal MRA finerenone at #ESCCongress Now in @NEJM nejm.org/doi/full/10.10…
51K
Muthu Vaduganathan
@mvaduganathan
May 5, 2022
🚨 #DELIVER, the largest trial of #HFpEF & #HFmrEF (n=6,263), has met its primary endpoint (CV death + worsening HF) extending #SGLT2i dapagliflozin benefits to the full spectrum of patients with HF. Stay tuned for full data presentation! @scottdsolomon astrazeneca.com/content/astraz…
Muthu Vaduganathan
@mvaduganathan
May 21, 2020
How do you communicate the expected lifetime benefits of HF therapies? New data in @TheLancet from 3 RCTs (#EMPHASISHF #PARADIGMHF #DAPAHF) estimate up to *6 years* of survival gains. Combination ARNI+BB+MRA+SGLT2i = new therapeutic standard in HFrEF. 📎thelancet.com/journals/lance…
Muthu Vaduganathan
@mvaduganathan
Sep 22, 2023
The #SGLTi have likely accrued the most indications of any class across biomedicine in recent regulatory history FDA approval for 6 drugs ✅ Glycemic control in T2D (5) ✅ CV risk reduction in T2D (3) ✅ HF irrespective of LVEF (3) ✅ CKD with or without T2D (2) ✅ CKD & T2D (2)
86K
Muthu Vaduganathan
@mvaduganathan
Oct 10, 2023
2023, the year the #GLP1RA semaglutide can’t lose! #FLOW, the kidney outcomes trial of once-weekly injectable semaglutide, has stopped early for overwhelming efficacy based on interim analysis Massive news, results in Q1 2024 novonordisk.com/content/nncorp…
73K
Muthu Vaduganathan
@mvaduganathan
Aug 5, 2024
*Breaking* P3 #FINEARTSHF meets its primary endpoint (CVd+total HF events)! Non-steroidal MRA finerenone "demonstrates definitive CV benefits" in HFmrEF & HFpEF Looking forward to presenting full results at #ESCCongress alongside @scottdsolomon @PSJhund bayer.com/media/en-us/fi…
45K
Muthu Vaduganathan
@mvaduganathan
Oct 6, 2025
Incredibly grateful to the impressive @MethodistHosp team for the kind invitation to present at GR Extra special my father, who trained there, could attend. He inspired me to become a cardiologist and has been a lifelong guide & ultimate role model 🙏🏾 🎥 m.youtube.com/watch?v=vlHjpX…
35K
Muthu Vaduganathan
@mvaduganathan
Apr 7, 2023
👀#HeartFailure2023 #LBCT Announced This will be THE🌎meeting for the latest in HF! 🔥 #PARAGLIDE + #PARAGON: a final word on #ARNI in #HFpEF 🔥 #FINEARTS: baseline data from largest #MRA RCT in #HFpEF 🔥 #DELIVER + #DAPAHF: #PAD #WinRatio #KCCQ 🔥 #NUDGEFLU: vaccination in #HF
57K
Muthu Vaduganathan
@mvaduganathan
Jun 5, 2025
🔥 #CONFIDENCE in @NEJM Simultaneous initiation of #SGLT2i + #nsMRA safely and rapidly delivers in patients with CKD & T2D A new age of combination therapies has arrived in #CKM care #ERA25 nejm.org/doi/full/10.10…
65K